| Jason Lattin, MD | |
|
240 Hospital Pl Ste 305, Soldotna, AK 99669-7559 | |
| (907) 714-4130 | |
| (844) 412-3946 |
| Full Name | Jason Lattin |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 21 Years |
| Location | 240 Hospital Pl Ste 305, Soldotna, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811010630 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD26612 (Oregon) | Secondary |
| 208600000X | Surgery | 7113 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Peninsula General Hospital | Soldotna, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Peninsula General Hospital Inc | 4587552575 | 85 |
News Archive
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced on June 15, 2010 that its 51% owned Suzhou Erye pharmaceutical subsidiary passed the government inspection by the State Food and Drug Administration ("SFDA") in China to manufacture penicillin and cephalosporin powder for injection at its new manufacturing facility.
Researchers from the Higher School of Economics conducted a meta-analysis by compiling data across 17 neuroimaging studies on working memory in children.
People with diabetes are risking their health by not discussing their use of complementary and alternative therapies with the health professionals managing their conventional treatment.
NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced dosing of the first patient in its Phase 2 clinical study of NGX-1998, a liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).
› Verified 3 days ago
| Entity Name | Central Peninsula General Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528062429 PECOS PAC ID: 4587552575 Enrollment ID: O20040310000598 |
News Archive
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced on June 15, 2010 that its 51% owned Suzhou Erye pharmaceutical subsidiary passed the government inspection by the State Food and Drug Administration ("SFDA") in China to manufacture penicillin and cephalosporin powder for injection at its new manufacturing facility.
Researchers from the Higher School of Economics conducted a meta-analysis by compiling data across 17 neuroimaging studies on working memory in children.
People with diabetes are risking their health by not discussing their use of complementary and alternative therapies with the health professionals managing their conventional treatment.
NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced dosing of the first patient in its Phase 2 clinical study of NGX-1998, a liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason Lattin, MD 289 N Fireweed St, Suite B, Soldotna, AK 99669-7540 Ph: (907) 714-4130 | Jason Lattin, MD 240 Hospital Pl Ste 305, Soldotna, AK 99669-7559 Ph: (907) 714-4130 |
News Archive
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced on June 15, 2010 that its 51% owned Suzhou Erye pharmaceutical subsidiary passed the government inspection by the State Food and Drug Administration ("SFDA") in China to manufacture penicillin and cephalosporin powder for injection at its new manufacturing facility.
Researchers from the Higher School of Economics conducted a meta-analysis by compiling data across 17 neuroimaging studies on working memory in children.
People with diabetes are risking their health by not discussing their use of complementary and alternative therapies with the health professionals managing their conventional treatment.
NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced dosing of the first patient in its Phase 2 clinical study of NGX-1998, a liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).
› Verified 3 days ago
Stephen G Jolley, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 271 Upper Rosian Dr, Soldotna, AK 99669 Phone: 907-382-4480 | |
Dr. David A King, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 240 Hospital Pl Ste 305, Soldotna, AK 99669 Phone: 907-714-4130 Fax: 844-412-3946 |